Primary-progressive multiple sclerosis (Q31130362)

29 June 2017

1 reference

title

Primary-progressive multiple sclerosis (English)

1 reference

primary progressive multiple sclerosis

29 June 2017

main subject

0 references

0 references

1

David H Miller

1 reference

29 June 2017

Siobhan M Leary

2

1 reference

29 June 2017

publication date

1 October 2007

1 reference

29 June 2017

1 reference

29 June 2017

volume

6

1 reference

29 June 2017

issue

10

1 reference

29 June 2017

page(s)

903-912

1 reference

Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study

29 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Relapses and progression of disability in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

The natural history of primary progressive MS in British Columbia, Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Clinical course of progressive multiple sclerosis in Brazilian patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Clinical and demographical characteristics of primary progressive multiple sclerosis in Isfahan, Iran

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Age at disability milestones in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Natural history of multiple sclerosis: a unifying concept

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Cigarette smoking and the progression of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Erythrocyte membrane fatty acids in benign and progressive forms of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its influence on prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

The presence of glutamic acid at positions 71 or 74 in pocket 4 of the HLA-DRbeta1 chain is associated with the clinical course of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

An immunogenetic heterogeneity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Familial effects on the clinical course of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of primary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Primary progressive multiple sclerosis as a phenotype of a PLP1 gene mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

A comparison of the pathology of primary and secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Remyelination is extensive in a subset of multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Cortical demyelination and diffuse white matter injury in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

The pathogenesis of primary progressive multiple sclerosis: antibody-mediated attack and no repair?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Clinical relevance of antibodies against myelin oligodendrocyte glycoprotein in different clinical types of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Post-mortem high-resolution MRI of the spinal cord in multiple sclerosis: a correlative study with conventional MRI, histopathology and clinical phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Serum levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in relapsing and primary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Immunological patterns identifying disease course and evolution in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Major differences in the dynamics of primary and secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Is inflammation important in early PPMS? a longitudinal MRI study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

The normal appearing grey matter in primary progressive multiple sclerosis: a magnetisation transfer imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Abnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Progressive change in primary progressive multiple sclerosis normal-appearing white matter: a serial diffusion magnetic resonance imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Normal-appearing brain t1 relaxation time predicts disability in early primary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Regional gray matter atrophy in early primary progressive multiple sclerosis: a voxel-based morphometry study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Primary progressive multiple sclerosis: a 5-year clinical and MR study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Axonal injury and overall tissue loss are not related in primary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Abnormalities of cerebral perfusion in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Deep Gray Matter Perfusion in Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Functional response to active and passive ankle movements with clinical correlations in patients with primary progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Spinal cord atrophy and disability in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Quantification of cervical cord pathology in primary progressive MS using diffusion tensor MRI.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

A comparison of neuropsychological deficits in primary and secondary progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Cognitive impairment in three subtypes of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Cognitive impairment in primary and secondary progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Discriminant analysis of the cognitive performance profile of MS patients differentiates their clinical course.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

A longitudinal study of cognition in primary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Primary and transitional progressive MS: a clinical and MRI cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

The PROMiSe trial: baseline data review and progress report.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Symptomatic therapy and neurorehabilitation in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Irreversible neurological worsening following high-dose corticosteroids in advanced progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Primary progressive multiple sclerosis : current and future treatment options

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Interferon beta-1b modulates serum sVCAM-1 levels in primary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Immunological studies of mitoxantrone in primary progressive MS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970243-0

7 January 2021

10.1016/S1474-4422(07)70243-0

Identifiers

DOI

1 reference

29 June 2017

1 reference